Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Sept. 14, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0611547/Nonalcoholic-Steatohepatitis-NASH-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Hardware,_Home_Improvement_&_Furnishing_Stores

Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market. The report identifies the key trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Nonalcoholic Steatohepatitis (NASH) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Nonalcoholic Steatohepatitis (NASH) Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Nonalcoholic Steatohepatitis (NASH) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Nonalcoholic Steatohepatitis (NASH) Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Nonalcoholic Steatohepatitis (NASH) Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Nonalcoholic Steatohepatitis (NASH) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Nonalcoholic Steatohepatitis (NASH) Therapeutics - Introduction 6

2.1 Disease Overview 6

2.2 Epidemiology 7

2.2.1 Quality of Life Parameters 8

2.2.2 Mortality 8

2.3 Etiology and Pathophysiology 8

2.4 Signs and Symptoms 11

2.5 Diagnosis 11

2.5.1 Ultrasonography 12

2.5.2 Computed Tomography 12

2.5.3 Magnetic Resonance Imaging 12

2.5.4 Liver function tests 12

2.5.5 Liver Biopsy 12

2.5.6 Trends in Diagnosis of NASH 13

2.6 Treatment and Management Options 13

2.6.1 Trends in the Treatment of NASH 15

2.6.2 Prevention 16

2.7 GlobalData Pipeline Report Guidance 17

3 NASH Therapeutics - Market Characterization 18

3.1 Overview 18

3.2 NASH Therapeutics Market Size (2005–2010) – Global 18

3.3 NASH Therapeutics Market Forecast (2010–2018) – Global 19

3.4 NASH Therapeutics Market Size (2005–2010) – The US 20

3.5 NASH Therapeutics Market Forecast (2010–2018) – The US 21

3.6 NASH Therapeutics Market Size (2005–2010) – France 22

3.7 NASH Therapeutics Market Forecast (2010–2018) – France 23

3.8 NASH Therapeutics Market Size (2005–2010) – Germany 24

3.9 NASH Therapeutics Market Forecast (2010–2018) – Germany 25

3.10 NASH Therapeutics Market Size (2005–2010) – Italy 26

3.11 NASH Therapeutics Market Forecast (2010–2018) – Italy 27

3.12 NASH Therapeutics Market Size (2005–2010) – Spain 28

3.13 NASH Therapeutics Market Forecast (2010–2018) – Spain 29

3.14 NASH Therapeutics Market Size (2005–2010) – The UK 30

3.15 NASH Therapeutics Market Forecast (2010–2018) – The UK 31

3.16 NASH Therapeutics Market Size (2005–2010) – Japan 32

3.17 NASH Therapeutics Market Forecast (2010–2018) – Japan 33

3.18 Drivers and Barriers for the NASH Therapeutics Market 34

3.18.1 Drivers for the NASH Therapeutics Market 34

3.18.2 Barriers for the NASH Therapeutics Market 34

3.19 Opportunity and Unmet Need Analysis 35

3.20 Key Takeaway 36

4 NASH Therapeutics - Competitive Assessment 37

4.1 Overview 37

4.2 Strategic Competitor Assessment 37

4.3 Product Profiles for the Major Off-Label Marketed Products in the NASH Market 38

4.3.1 Antioxidants 38

4.3.2 Anti-Diabetes Medications 39

4.3.3 Anti-Obesity Medications 40

4.3.4 Antihyperlipidemics 40

4.4 Key Takeaway 41

5 NASH Therapeutics - Pipeline Assessment 42

5.1 Overview 42

5.2 Strategic Pipeline Assessment 42

5.3 NASH Therapeutics Pipeline – Pipeline by Phases of Development 42

5.3.1 NASH Therapeutics – Phase III Pipeline 43

5.3.2 NASH Therapeutics – Phase II Pipeline 43

5.3.3 NASH Therapeutics – Phase I Pipeline 44

5.3.4 NASH Market – Discovery and Pre-Clinical Pipeline 44

5.4 NASH Therapeutics Market – Pipeline by Mechanism of Action 45

5.5 Technology Trends Analytic Framework 46

5.6 NASH Therapeutics – Promising Drugs Under Development 47

5.7 Molecule Profile for Promising Drugs Under Development 48

5.7.1 GS 9450 (LB84451) 48

5.7.2 DR Cysteamine (Delayed Release Cysteamine Bitartrate) 49

5.7.3 EGS21 (?-glucosylceramide formulation) 50

5.7.4 Anti-CD3 Monoclonal Antibody (aCD3 MAb, OKT3) 51

5.8 Key Takeaway 52

6 NASH Therapeutics - Clinical Trials Mapping 53

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 53

6.2 Clinical Trials by Phase 54

6.3 Clinical Trials by Trial Status 55

6.4 Prominent Sponsors 56

6.5 Top Companies Participating in NASH Therapeutics Clinical Trials 57

7 Strategic Assessment 59

7.1 Key Events Impacting the Future Market 59

7.2 NASH Therapeutics - Implications for Future Market Competition 60

8 NASH Therapeutics - Future Players 62

8.1 Introduction 62

8.2 Company Profiles 62

8.2.1 Raptor Pharmaceutical Corp. 62

8.2.2 Gilead Sciences, Inc. 64

8.2.3 Enzo Biochem, Inc. 67

9 NASH Therapeutics - Appendix 69

9.1 Market Definitions 69

9.2 Abbreviations 69

9.3 Methodology 71

9.3.1 Coverage 72

9.3.2 Secondary Research 72

9.3.3 Forecasting 72

9.3.4 Primary Research 74

9.3.5 Expert Panel Validation 74

9.4 Contact Us 74

9.5 Disclaimer 74

9.6 Bibliography 75

1.1 List of Tables

Table 1: NASH Therapeutics Market, Global, Prevalence of Liver Abnormalities Among Obese, Diabetic and General Population (%) 7

Table 2: NASH Therapeutics Market, Global, Prevalence of Parameters (%) of Metabolic Syndromes in Nonalcoholic Steatohepatitis 7

Table 3: Grading and Staging of NASH 10

Table 4: Therapeutic Options for the Treatment of NASH 14

Table 5: NASH Therapeutics Market, Global, Revenue ($m), 2005–2010 18

Table 6: NASH Therapeutics Market, Global, Forecast ($m), 2010–2018 19

Table 7: NASH Therapeutics Market, The US, Revenue ($m), 2005–2010 20

Table 8: NASH Therapeutics Market, The US, Forecast ($m), 2010–2018 21

Table 9: NASH Therapeutics Market, France, Revenue ($m), 2005–2010 22

Table 10: NASH Therapeutics Market, France, Forecast ($m), 2010–2018 23

Table 11: NASH Therapeutics Market, Germany, Revenue ($m), 2005–2010 24

Table 12: NASH Therapeutics Market, Germany, Forecast ($m), 2010–2018 25

Table 13: NASH Therapeutics Market, Italy, Revenue ($m), 2005–2010 26

Table 14: NASH Therapeutics Market, Italy, Forecast ($m), 2010–2018 27

Table 15: NASH Therapeutics Market, Spain, Revenue ($m), 2005–2010 28

Table 16: NASH Therapeutics Market, Spain, Forecast ($m), 2010–2018 29

Table 17: NASH Therapeutics Market, The UK, Revenue ($m), 2005–2010 30

Table 18: NASH Therapeutics Market, The UK, Forecast ($m), 2010–2018 31

Table 19: NASH Therapeutics Market, Japan, Revenue ($m), 2005–2010 32

Table 20: NASH Therapeutics Market, Japan, Forecast ($m), 2010–2018 33

Table 21: NASH Therapeutics, Phase III Pipeline, 2011 43

Table 22: NASH Therapeutics, Phase II Pipeline, 2011 43

Table 23: NASH Therapeutics, Phase I Pipeline, 2011 44

Table 24: NASH Therapeutics, Discovery and Pre-Clinical Pipeline, 2011 44

Table 25: NASH Therapeutics – Most Promising Drugs Under Development, 2011 47

Table 26: NASH Therapeutics, Clinical Trials by Country, 2011 53

Table 27: NASH Therapeutics, Clinical Trials by Phase, 2011 54

Table 28: NASH Therapeutics, Clinical Trials by Status of Development, 2011 55

Table 29: NASH Therapeutics, Prominent Sponsors, 2011 57

Table 30: NASH Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 58

Table 31: Raptor Pharmaceutical Corp., Liver Disease Management, Pipeline, 2011 63

Table 32: Raptor Pharmaceutical Corp., Deals, 2009–2011 63

Table 33: Gilead Sciences, Inc., Liver Disease Management, Pipeline, 2011 65

Table 34: Gilead Sciences, Inc., Deals, 2009-2011 65

Table 35: Enzo Biochem, Inc., Liver Disease Management, Pipeline, 2011 68

Table 36: Enzo Biochem, Inc., Deals, 2009-2011 68

1.2 List of Figures

Figure 1: Spectrum of NAFLD 6

Figure 2: Two-Hit Hypothesis of NASH Pathogenesis 8

Figure 3: Mechanisms Leading to Liver Steatosis 9

Figure 4: Factors Contributing to the Development of NASH from a Steatotic Liver 10

Figure 5: Treatment Targets for NASH 14

Figure 6: NASH Therapeutics – Referral Pathway 16

Figure 7: NASH Therapeutics Market, Global, Revenue ($m), 2005–2010 18

Figure 8: NASH Therapeutics Market, Global, Forecast ($m), 2010–2018 19

Figure 9: NASH Therapeutics Market, The US, Revenue ($m), 2005–2010 20

Figure 10: NASH Therapeutics Market, The US, Forecast ($m), 2010–2018 21

Figure 11: NASH Therapeutics Market, France, Revenue ($m), 2005–2010 22

Figure 12: NASH Therapeutics Market, France, Forecast ($m), 2010–2018 23

Figure 13: NASH Therapeutics Market, Germany, Revenue ($m), 2005–2010 24

Figure 14: NASH Therapeutics Market, Germany, Forecast ($m), 2010–2018 25

Figure 15: NASH Therapeutics Market, Italy, Revenue ($m), 2005–2010 26

Figure 16: NASH Therapeutics Market, Italy, Forecast ($m), 2010–2018 27

Figure 17: NASH Therapeutics Market, Spain, Revenue ($m), 2005–2010 28

Figure 18: NASH Therapeutics Market, Spain, Forecast ($m), 2010–2018 29

Figure 19: NASH Therapeutics Market, The UK, Revenue ($m), 2005–2010 30

Figure 20: NASH Therapeutics Market, The UK, Forecast ($m), 2010–2018 31

Figure 21: NASH Therapeutics Market, Japan, Revenue ($m), 2005-2010 32

Figure 22: NASH Therapeutics Market, Japan, Forecast ($m), 2010-2018 33

Figure 23: Opportunity and Unmet Need in the NASH Therapeutics Market, 2010 36

Figure 24: NASH Therapeutics, Strategic Competitor Assessment, 2010 38

Figure 25: NASH Therapeutics – Pipeline by Phase of Development, 2011 42

Figure 26: NASH Therapeutics, Pipeline by Mechanism of Action (%), 2011 45

Figure 27: NASH Therapeutics, Technology Trends Analytics Framework, 2011 46

Figure 28: NASH Therapeutics, Technology Trends Analytics Framework, Description, 2011 47

Figure 29: NASH Therapeutics, Clinical Trials by Country, 2011 53

Figure 30: NASH Therapeutics, Clinical Trials by Phase (%), 2011 54

Figure 31: NASH Therapeutics, Clinical Trials by Status of Development (%), 2011 55

Figure 32: NASH Therapeutics, Overall Sponsors (%), 2011 56

Figure 33: NASH Therapeutics, Prominent Sponsors (%), 2011 56

Figure 34: NASH Therapeutics, Top Companies Participating in Clinical Trials, 2011 57

Figure 35: NASH Therapeutics Market, Drivers and Restraints, 2011 59

Figure 36: Implications for Future Market Competition in the NASH Market, 2011 60

Figure 37: NASH Therapeutics Market, Pipeline by Company, 2011 62

Companies mentioned

Raptor Pharmaceutical Corp.

Gilead Sciences, Inc.

Enzo Biochem, Inc.

To order this report:

Hardware, Home Improvement & Furnishing Stores Industry: Nonalcoholic Steatohepatitis (NASH) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Hardware, Home Improvement & Furnishing Stores Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker